BioMarin Pharmaceutical Inc.
BMRNHealthcareNASDAQBiotechnology · Last scanned Oct 21, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of Oct 20
Headquartered within the healthcare sector, BioMarin Pharmaceutical Inc. focuses on Biotechnology services and products. BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States,. The company carries a $10.93B market cap, placing it firmly in the large-cap category. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations.
Market Cap
$10.93B
Beta
0.21
P/E (TTM)
152.54
P/E (Fwd)
8.50
EPS (TTM)
$0.37
EPS (Fwd)
$6.64
ROE
1.2%
ROA
3.3%
Cash
$874.0M
Total Debt
$4.20B
Free CF
$85.2M
52W Change
5.8%
Annual Financials
Cash vs Debt
Where BMRN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, BMRN finished 6.35% below its 150-day moving average ($58.38) and 6.61% below its 200-day moving average ($58.54). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BMRN overbought or oversold?
At the October 20, 2026 close, BMRN's RSI(14) was 25.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, BMRN has $874.0M in cash with $4.20B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $85.2M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 1.2% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 3.3% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $2.10B (2022) to $3.22B (2025), reflecting a 54% increase over the period.
BMRN's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. At over 50x earnings, BMRN carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for BioMarin Pharmaceutical Inc. and its sector.